The science
CJC-1295 Ipamorelin Research: The Mechanism and the Evidence
Two receptors, one cell, a supra-additive pulse — and a careful note on what was studied as a blend (nothing) versus what was studied as components (a great deal).
Start here
The CJC-1295 Ipamorelin research comes down to a two-switch story. The pituitary gland makes growth hormone (GH), and two separate switches turn that release up. CJC-1295 flips the first switch — the GHRH receptor — and because of a feature called DAC it stays flipped for days. Ipamorelin flips the second switch — the ghrelin receptor — and produces a quick burst. Flip both and the gland releases more GH than either switch manages alone; that extra-large combined effect is called supra-additive, or synergy. This page walks through the receptor mechanism, the human evidence for the synergy, the chemistry that gives CJC-1295 its long life, and what each peptide showed on its own. One rule runs through all of it: every finding here is attributed to a study of a single component or to general synergy work, because the fixed blend itself has never been trialed.
Cjc-1295 ipamorelin
The term cjc-1295 ipamorelin names a research combination of two distinct molecules. CJC-1295 is a tetra-substituted analogue of the natural GHRH fragment hGRF(1-29); ipamorelin is a synthetic pentapeptide (a five-amino-acid chain, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2). CJC-1295 binds the GHRH receptor, a class-B G-protein-coupled receptor on the pituitary's GH-making cells (somatotrophs), raising the second messenger cAMP and driving GH synthesis and release. Ipamorelin binds GHS-R1a, the ghrelin receptor on the same cells, raising intracellular calcium through a different pathway. Two doors, one room — and that independence is the entire mechanistic basis for combining them [3] [4].
Ipamorelin cjc 1295
Stated as ipamorelin cjc 1295, the order of the names does not change the pharmacology, but it does foreground the secretagogue this monograph leads with. Ipamorelin's defining property is selectivity: it releases GH without raising ACTH or cortisol above GHRH-stimulated levels, even at more than 200 times the dose needed for half its GH effect, while matching the older GHRP-6's GH efficacy in swine [2]. Paired with the long-acting GHRH analogue CJC-1295, the intent is a clean, frequent GH pulse riding on a multi-day GHRH background. The pairing's logic is sound on paper; its real-world pulse profile remains uncharacterized in any controlled study.
The dual-receptor mechanism and its synergy
The synergy is documented in humans and explained in cells. In normal men, submaximal doses of a growth-hormone-releasing peptide (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) stimulated GH release synergistically, the two acting through independent mechanisms [3] — the foundational human evidence that a GHRP-plus-GHRH combination produces more GH than the sum of its parts. The receptor-level explanation followed: co-activating the cloned GHRH receptor and the ghrelin receptor in transfected cells produced a cAMP response roughly twice that of GHRH-receptor activation alone, suggesting direct receptor cross-talk [4]. Mechanistically, the ghrelin arm also opposes somatostatin, the brake the body normally applies to GH — releasing that brake while pressing the GHRH accelerator is why the combined pulse is large.
Cjc 1295 dac
The cjc 1295 dac form is what gives this peptide its days-long action. CJC-1295 carries a C-terminal maleimidopropionamide-lysine — a Drug Affinity Complex, or DAC — that covalently bonds to Cys34 of serum albumin (a long-lived blood protein) after injection. In rats this bioconjugation produced about a four-fold increase in GH area-under-the-curve over two hours versus the unmodified GHRH fragment, with albumin-bound peptide still detectable in plasma beyond 72 hours [5]. In healthy adults, a single subcutaneous dose of CJC-1295 with DAC raised GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. The DAC is the single feature that separates the long-acting CJC-1295 from its short-acting, no-DAC cousin Mod GRF (1-29).
Cjc ipamorelin
Shortened to cjc ipamorelin, the combination's appeal is the union of a durable background and a clean spike. Beyond GH release, ipamorelin has shown effects worth recording. It dose-dependently increased longitudinal bone-growth rate in adult female rats (from roughly 42 to 52 µm/day over 15 days), an effect attributable to GH release [9], and it counteracted glucocorticoid-induced bone loss in rats, raising periosteal bone-formation rate four-fold versus glucocorticoid alone [11]. It also has a GH-independent action: in a rat model of post-surgical gut paralysis, repeated ipamorelin increased fecal output, food intake, and weight gain through the ghrelin receptor directly [10] — a reminder that the ghrelin arm does more than release GH.
Cjc 1295 and ipamorelin
Searched as cjc 1295 and ipamorelin, readers usually want to know what the pair does together — and the honest answer is that no controlled human trial has ever tested the pre-mixed combination. CJC-1295 with DAC reached Phase 2 before development was discontinued; ipamorelin was investigated (including a post-operative-ileus program) but never advanced to approval. The combination's case is therefore built entirely from each compound's separate literature [1] [2] [5] plus the general GHRH-plus-GHRP synergy evidence [3] [4]. This monograph states that limit plainly rather than papering over it: the components are well studied; the fixed blend is not.
Pharmacokinetics and disposition
The two halves keep different clocks, and the data is rodent-heavy. Ipamorelin's plasma clearance is roughly five-fold lower than GHRP-6's in rats, with 60 to 80% of a dose recovered in bile and urine [8]; its plasma presence is under about two hours in rodents, with a peak GH response near 40 minutes — and no validated human half-life has been published. CJC-1295 with DAC, by contrast, persists for days through albumin binding [5], while the no-DAC Mod GRF (1-29) is cleared in minutes-to-roughly-30-minutes through DPP-IV cleavage (an enzyme that snips native GHRH). Across the broader GH-secretagogue class, a safety review found the compounds generally well tolerated, with increased blood glucose from decreased insulin sensitivity the chief concern and long-term cancer and mortality data still needed [6].
Where the field is going
Recent literature keeps these peptides in view as investigational tools rather than therapies. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance examined ipamorelin as a GH-axis secretagogue with preclinical metabolic and tissue-repair signals, while emphasizing the absence of rigorous human trials and the potential for serious harm. The ipamorelin scaffold has also proven chemically robust: it served as a backbone for boron-rich ghrelin-receptor-targeting conjugates that retained receptor activation [13], and as one of several secretagogue scaffolds tested for fluorine-18 PET imaging of the ghrelin receptor (the reported affinity values there belong to a different analogue, not to ipamorelin) [14]. Analytical work has likewise tracked glycine-modified ipamorelin analogues in seized doping material, underscoring that anti-doping panels must keep pace with modified secretagogues [12].